Gallbladder Disease on Mounjaro (tirzepatide for T2D): Week-by-Week Timeline of What to Expect

What the label's 0.6% figure covers

The warning for acute gallbladder disease reports that cholelithiasis, biliary colic and cholecystectomy were reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients in adult placebo-controlled clinical trials [1]. Those three events are counted together, so 0.6% is a combined rate rather than a stone-specific one. The warning gives the rate for Mounjaro-treated patients as a group rather than as separate figures for 5 mg, 10 mg and 15 mg, or by week of treatment [1].

The label's only timing statement about side effects concerns gastrointestinal reactions: most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. It makes no such statement for gallbladder disease. The label also notes that adverse reaction rates from its clinical trials cannot be directly compared with rates from trials of other drugs, and may not reflect rates seen in practice [1].

Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events. It is not labeled for weight loss [1].

What the pooled trial data show

A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants, of whom 6,828 received tirzepatide and 3,043 were controls [2]. Tirzepatide was associated with a higher risk of the composite of gallbladder or biliary disease compared with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42). The same analysis did not find a statistically significant increase for cholelithiasis, cholecystitis or biliary disease when each was assessed separately [2].

A separate meta-analysis of 13 randomized trials in 26,894 people with obesity but without diabetes found no significant biliary risk with tirzepatide. Semaglutide was associated with more gallbladder-related disorders, particularly cholelithiasis (risk ratio over 2.6; 95% CI 1.40 to 4.82) [3]. That population differs from the type 2 diabetes population in which Mounjaro is used.

A review of GLP-1-based therapies, including tirzepatide, notes that these drugs affect gallbladder function and may increase the risk of biliary disease [4].

If gallstones are suspected

The label's statement for suspected cholelithiasis is diagnostic: gallbladder diagnostic studies and clinical follow-up are indicated [1]. Acute pancreatitis is handled under a separate warning, which says to discontinue Mounjaro if pancreatitis is suspected. The label does not give a general statement to discontinue Mounjaro for suspected gallstones [1].